Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Biomarker Discovery & Validation › Pfizer's Ibrance Shows 'Modest' Antitumor Activity in Patients With CDKN2A-Altered Lung Cancer

Pfizer's Ibrance Shows 'Modest' Antitumor Activity in Patients With CDKN2A-Altered Lung Cancer

Jul 01, 2020
|
staff reporter

NEW YORK – Investigators from the Targeted Agent and Profiling Utilization Registry (TAPUR) study have shown that palbociclib (Pfizer's Ibrance) shows activity in some non-small cell lung cancer patients with alterations in CDKN2A.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

What's Popular?

In Cancer

  1. FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

  2. Bio-Path Holdings Doses First Patient in Phase I Lymphoma, Leukemia Trial

  3. Qiagen to Develop Companion Diagnostic for BioNTech Head, Neck Cancer Treatment

  4. Exceptional Responders Cancer Study Points to Possible Treatment Targets

    Premium

  5. AUM Biosciences, Newsoara Biopharma Partner on Targeted Cancer Drug Development in Greater China

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.